Literature DB >> 17644310

COMT Val158Met polymorphism predicts negative symptoms response to treatment with olanzapine in schizophrenia.

Alessandro Bertolino, Grazia Caforio, Giuseppe Blasi, Antonio Rampino, Marcello Nardini, Daniel R Weinberger, Bruno Dallapiccola, Lorenzo Sinibaldi, Sophia Douzgou.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17644310     DOI： 10.1016/j.schres.2007.06.014

Source DB:  PubMed          Journal:  Schizophr Res        ISSN： 0920-9964            Impact factor:   4.939


× No keyword cloud information.
  16 in total

Review 1.  Pharmacogenetics and antipsychotics: therapeutic efficacy and side effects prediction.

Authors:  Jian-Ping Zhang; Anil K Malhotra
Journal:  Expert Opin Drug Metab Toxicol       Date:  2011-01       Impact factor: 4.481

2.  DRD2/AKT1 interaction on D2 c-AMP independent signaling, attentional processing, and response to olanzapine treatment in schizophrenia.

Authors:  Giuseppe Blasi; Francesco Napolitano; Gianluca Ursini; Paolo Taurisano; Raffaella Romano; Grazia Caforio; Leonardo Fazio; Barbara Gelao; Annabella Di Giorgio; Luisa Iacovelli; Lorenzo Sinibaldi; Teresa Popolizio; Alessandro Usiello; Alessandro Bertolino
Journal:  Proc Natl Acad Sci U S A       Date:  2010-12-27       Impact factor: 11.205

Review 3.  The promise and reality of pharmacogenetics in psychiatry.

Authors:  Peter P Zandi; Jennifer T Judy
Journal:  Psychiatr Clin North Am       Date:  2010-03

Review 4.  Pharmacogenetics of antipsychotics.

Authors:  Eva J Brandl; James L Kennedy; Daniel J Müller
Journal:  Can J Psychiatry       Date:  2014-02       Impact factor: 4.356

5.  The pharmacogenetics of symptom response to antipsychotic drugs.

Authors:  Gavin P Reynolds
Journal:  Psychiatry Investig       Date:  2012-01-09       Impact factor: 2.505

6.  Dopamine transporter gene variant affecting expression in human brain is associated with bipolar disorder.

Authors:  Julia K Pinsonneault; Dawn D Han; Katherine E Burdick; Maria Kataki; Alessandro Bertolino; Anil K Malhotra; Howard H Gu; Wolfgang Sadee
Journal:  Neuropsychopharmacology       Date:  2011-04-27       Impact factor: 7.853

7.  Pharmacogenetics of Antipsychotic Treatment in Schizophrenia.

Authors:  Samar S M Elsheikh; Daniel J Müller; Jennie G Pouget
Journal:  Methods Mol Biol       Date:  2022

8.  Association between catechol-O-methyltrasferase Val108/158Met genotype and prefrontal hemodynamic response in schizophrenia.

Authors:  Ryu Takizawa; Mamoru Tochigi; Yuki Kawakubo; Kohei Marumo; Tsukasa Sasaki; Masato Fukuda; Kiyoto Kasai
Journal:  PLoS One       Date:  2009-05-08       Impact factor: 3.240

9.  Genetic variation in COMT activity impacts learning and dopamine release capacity in the striatum.

Authors:  Eleanor H Simpson; Julia Morud; Vanessa Winiger; Dominik Biezonski; Judy P Zhu; Mary Elizabeth Bach; Gael Malleret; H Jonathan Polan; Scott Ng-Evans; Paul E M Phillips; Christoph Kellendonk; Eric R Kandel
Journal:  Learn Mem       Date:  2014-03-17       Impact factor: 2.460

10.  Association of dopamine-related genetic loci to dopamine D3 receptor antagonist ABT-925 clinical response.

Authors:  A Bhathena; Y Wang; J B Kraft; K B Idler; S J Abel; R R Holley-Shanks; W Z Robieson; B Spear; L Redden; D A Katz
Journal:  Transl Psychiatry       Date:  2013-04-09       Impact factor: 6.222
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.